189 related articles for article (PubMed ID: 32178618)
1. Ustekinumab-induced Sarcoidosis in a Patient with Psoriatic Arthritis.
Kobak S; Semiz H
Curr Drug Saf; 2020; 15(2):163-166. PubMed ID: 32178618
[TBL] [Abstract][Full Text] [Related]
2. How effective is ustekinumab in controlling psoriatic arthritis?
Bonifati C; Graceffa D
Dermatol Ther; 2016 May; 29(3):155-9. PubMed ID: 26626908
[TBL] [Abstract][Full Text] [Related]
3. [Acute sarcoid myopathy and neuropathy aggravated by ustekinumab administration in an elderly woman with psoriasis and systemic sarcoidosis].
Sano H; Maeda T; Sato R; Shimizu F; Koga M; Kanda T
Rinsho Shinkeigaku; 2022 Jun; 62(6):475-480. PubMed ID: 35644583
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
Ghosh S; Gensler LS; Yang Z; Gasink C; Chakravarty SD; Farahi K; Ramachandran P; Ott E; Strober BE
Drug Saf; 2019 Jun; 42(6):751-768. PubMed ID: 30739254
[TBL] [Abstract][Full Text] [Related]
5. Sarcoid- like Phenomenon - ustekinumab induced granulomatous reaction mimicking diffuse metastatic disease: a case report and review of the literature.
Gad MM; Bazarbashi N; Kaur M; Gupta A
J Med Case Rep; 2019 Jul; 13(1):257. PubMed ID: 31358038
[TBL] [Abstract][Full Text] [Related]
6. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
7. Co-occurrence of rheumatoid arthritis and sarcoidosis.
Kobak Ş; Karaarslan AA; Yilmaz H; Sever F
BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26150618
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
[TBL] [Abstract][Full Text] [Related]
9. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial.
Kavanaugh A; Puig L; Gottlieb AB; Ritchlin C; Li S; Wang Y; Mendelsohn AM; Song M; Zhu Y; Rahman P; McInnes IB;
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1739-49. PubMed ID: 26097039
[TBL] [Abstract][Full Text] [Related]
11. Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: A case report.
Nicocia G; Bonanno C; Lupica A; Toscano A; Rodolico C
Neuromuscul Disord; 2020 Mar; 30(3):246-249. PubMed ID: 32057636
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis.
Torres T; Faria R
Drug Dev Res; 2015 Dec; 76(8):428-31. PubMed ID: 26372543
[TBL] [Abstract][Full Text] [Related]
13. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
McInnes IB; Kavanaugh A; Gottlieb AB; Puig L; Rahman P; Ritchlin C; Brodmerkel C; Li S; Wang Y; Mendelsohn AM; Doyle MK;
Lancet; 2013 Aug; 382(9894):780-9. PubMed ID: 23769296
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
Siebert S; Sweet K; Dasgupta B; Campbell K; McInnes IB; Loza MJ
Arthritis Rheumatol; 2019 Oct; 71(10):1660-1669. PubMed ID: 31070869
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).
Kavanaugh A; Puig L; Gottlieb AB; Ritchlin C; You Y; Li S; Song M; Randazzo B; Rahman P; McInnes IB
Ann Rheum Dis; 2016 Nov; 75(11):1984-1988. PubMed ID: 27098404
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
[TBL] [Abstract][Full Text] [Related]
18. Ustekinumab associated chronic eosinophilic pneumonia.
Kalra SS; Chizinga M; Trillo-Alvarez C; Papierniak ES
J Asthma; 2021 Dec; 58(12):1670-1674. PubMed ID: 32962463
[TBL] [Abstract][Full Text] [Related]
19. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis.
Zabotti A; Goletti D; Lubrano E; Cantini F
Expert Opin Drug Saf; 2020 Jan; 19(1):69-82. PubMed ID: 31847608
[No Abstract] [Full Text] [Related]
20. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab.
Nakayama C; Fujita Y; Watanabe M; Shimizu H
J Dermatol; 2015 Oct; 42(10):996-8. PubMed ID: 26010891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
